Oncolytic Immunotherapy: Where Are We Clinically?
Author
Source
Issue
Vol. 2014, Issue 2014 (31 Dec. 2014), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2014-01-16
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Abstract EN
Following a century of preclinical and clinical work, oncolytic viruses are now proving themselves in randomized phase 3 trials.
Interestingly, human data indicates that these agents have potent immunostimulatory activity, raising the possibility that the key consequence of oncolysis might be induction of antitumor immunity, especially in the context of viruses harboring immunostimulatory transgenes.
While safety and efficacy of many types of oncolytic viruses, including adenovirus, herpes, reo, and vaccinia seem promising, few mechanisms of action studies have been performed with human substrates.
Thus, the relative contribution of “pure” oncolysis, the immune response resulting from oncolysis, and the added benefit of adding a transgene remain poorly understood.
Here, the available clinical data on oncolytic viruses is reviewed, with emphasis on immunological aspects.
American Psychological Association (APA)
Hemminki, Akseli. 2014. Oncolytic Immunotherapy: Where Are We Clinically?. Scientifica،Vol. 2014, no. 2014, pp.1-7.
https://search.emarefa.net/detail/BIM-1047597
Modern Language Association (MLA)
Hemminki, Akseli. Oncolytic Immunotherapy: Where Are We Clinically?. Scientifica No. 2014 (2014), pp.1-7.
https://search.emarefa.net/detail/BIM-1047597
American Medical Association (AMA)
Hemminki, Akseli. Oncolytic Immunotherapy: Where Are We Clinically?. Scientifica. 2014. Vol. 2014, no. 2014, pp.1-7.
https://search.emarefa.net/detail/BIM-1047597
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1047597